Browsing Tag
Astellas Pharma Inc.
7 posts
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.
Bladder cancer breakthrough: FDA gives Priority Review to Merck’s KEYTRUDA and KEYTRUDA QLEX + PADCEV combinations
Find out how Merck’s KEYTRUDA and new KEYTRUDA QLEX + PADCEV combinations are set to transform treatment for muscle-invasive bladder cancer — read more now
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
Astellas Pharma and MRI partner to accelerate global expansion of Japanese drug discovery startups
Astellas Pharma and Mitsubishi Research Institute partner to accelerate Japan’s drug discovery startups under MEDISO, offering global access and lab support.
EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC’s) approval of…
Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or…
Astellas Pharma embraces HPE Asset Upcycling Services for environmental stewardship
In a significant stride towards sustainable IT solutions, Hewlett Packard Enterprise (HPE) has partnered with Astellas Pharma Inc.,…